Several headwinds have pushed Regeneron 's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron's stock has dropped 40% due to EYLEA's IP issues, but strong financials and pipeline assets bolster optimism for long-term growth. Dupixent's robust sales growth and potential new ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion, while the ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report second-quarter results on Aug 1, 2024. The Zacks Consensus Estimate for second-quarter revenues is pegged at $3.38 billion, while ...

Regeneron announced that it has entered into a global collaboration agreement with Tessera Therapeutics to commercialize and ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...